| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Rapamycin | CTRPv2 | pan-cancer | AAC | 0.19 | 4e-07 |
| mRNA | OSI-906 | CTRPv2 | pan-cancer | AAC | 0.18 | 2e-06 |
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | -0.18 | 2e-05 |
| mRNA | GSK690693 | GDSC1000 | pan-cancer | AAC | 0.15 | 2e-05 |
| mRNA | pitstop2 | CTRPv2 | pan-cancer | AAC | 0.2 | 3e-05 |
| mRNA | A-443654 | GDSC1000 | pan-cancer | AAC | 0.23 | 5e-05 |
| mRNA | BMS-754807 | CTRPv2 | pan-cancer | AAC | 0.15 | 6e-05 |
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | -0.15 | 7e-05 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.15 | 7e-05 |
| mRNA | CAL-101 | GDSC1000 | pan-cancer | AAC | 0.14 | 9e-05 |